CLSDQ — Clearside Biomedical, Share News
0.000.00%
Last trade - 00:00- $1.31m
- $55.68m
- $1.66m
Clearside Biomedical Inc expected to post a loss of 10 cents a share - Earnings Preview
Clearside Biomedical Inc reports results for the quarter - Earnings Summary
Clearside Biomedical Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement With Santen Pharmaceutical
U.S. RESEARCH ROUNDUP-Abbott, Gilead, Roku
U.S. STOCKS ON THE MOVE-Boeing, Banzai, Norwegian Cruise Line
U.S. STOCKS ON THE MOVE-Alphabet, Boeing, Arcadium Lithium
Brief: Clearside Biomedical Announces Positive Topline Results From Odyssey Phase 2B Trial Of Suprachoroidal Cls-Ax In Wet AMD Achieving All Primary And Secondary Outcomes
Clearside jumps as eye disease drug succeeds in mid-stage trial
Brief: Clearside Biomedical Announces Completion Of Final Participant Visit In Odyssey Phase 2B Trial Of CLS-AX
Clearside Biomedical Inc reports results for the quarter ended in June - Earnings Summary
Clearside Biomedical Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Clearside Biomedical Arctic Vision Says New Drug Applications For Arcatus Officially Accepted In Australia And Singapore
Brief: Clearside Biomedical Appoints Dr. Glenn Yiu To Its Scientific Advisory Board
Clearside Biomedical Inc expected to post a loss of 14 cents a share - Earnings Preview
Clearside Biomedical Inc reports results for the quarter ended in December - Earnings Summary
Clearside Biomedical Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Clearside Biomedical Completes Recruitment In ODYSSEY Phase 2b Clinical Trial Of CLS-AX In Wet AMD
U.S. STOCKS ON THE MOVE-Moderna, Aldeyra Therapeutics, Colgate-Palmolive